PBYI (Puma Biotechnology) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBYI Puma Biotechnology Inc PBYI
55 GF Score
Price $7.99
GF Value $3.34
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Puma Biotechnology Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

PBYI
55GF Score
Puma Biotechnology Inc PBYI
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Puma Biotechnology (PBYI) Overvalued in 2026?

Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued. The current stock price of $7.99 is trading 139.2% above its estimated GF Value™ of $3.34. GuruFocus considers Puma Biotechnology to be Significantly Overvalued.

Key valuation signals for PBYI:

  • Dividend-Payout-to-FFO:
  • GF Value™: $3.34 vs. price of $7.99 (139.2% above fair value)
  • GF Score™: 55/100 with 9 warning signs

No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Puma Biotechnology Business Description

Address 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
55GF Score

Get the complete analysis for PBYI

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.99
Price
$3.34
GF Value